The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via σ 1 receptor activation: Comparison with the effects of dextromethorphan

British Journal of Pharmacology

Volumn 144, Issue 7, 2005, Pages 908-918

  Shin, Eun Joo ^a   Nah, Seung Yeol ^b   Kim, Won Ki ^c   Ko, Kwang Ho ^d   Jhoo, Wang Kee ^a   Lim, Yong Kwang ^a   Cha, Joo Young ^a   Chen, Chieh Fu ^e   Kim, Hyoung Chun ^a  

^a Kangwon National University   (South Korea)

^b Konkuk University   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

1 Receptor; Anticonvulsants; AP 1 DNA binding activity; Conditioned place preference; Dextromethorphan; Dimemorfan; Hippocampus; Kainate; Neuronal cell loss; Phencyclidine

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; [1 (2 THIENYL)CYCLOHEXYL]PIPERIDINE; ANTICONVULSIVE AGENT; DEXTROMETHORPHAN; DEXTRORPHAN; DIMEMORFAN; DIZOCILPINE; DNA; HALOPERIDOL; IFENPRODIL; KAINIC ACID; MESSENGER RNA; N [2 (2,3 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N ALLYLNORMETAZOCINE; OPIATE ANTAGONIST; PHENCYCLIDINE; PROTEIN C FOS; PROTEIN C JUN; RADIOLIGAND; SIGMA 1 OPIATE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; NORTHERN BLOTTING; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; RAT; RECEPTOR AFFINITY; SEIZURE; WESTERN BLOTTING;

ANIMALS; DEXTROMETHORPHAN; KAINIC ACID; MALE; MICE; MICE, INBRED C57BL; MORPHINANS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; SEIZURES;

EID: 17844377593     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705998     Document Type: Article

References (64)

1. 2+ channels and in gerbil global cerebral ischemia. Eur. J. Pharmacol., 299, 103-112.
2. BEN-ARI, Y. (1985). Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience, 14, 375-403.
3. BING, G., WILSON, B., HUDSON, P., JIN, L., FENG, Z., ZHANG, W., BING, R. & HONG, J.S. (1997). A single dose of kainic acid elevates the levels of enkephalins and activator protein-1 transcription factors in the hippocampus for up to 1 year. Proc. Natl. Acad. Sci. U.S.A., 94, 9422-9427.
4. BOHAM, D., BOS, T.J., ADMON, A., NISHIMURA, T., VOGT, P.K. & TJIAN, R. (1987). Human proto-oncogene c-jun encodes a DNA-binding protein with structural and functional properties of transcription factor AP-1. Science, 238, 1386-1392.
5. BOWEN, W.D., HELLEWELL, S.B. & MCGARRY, K. (1989). Evidence for a multi-site model of the rat brain σ receptor. Eur. J. Pharmacol., 163, 309-318.
6. 3H]-(+)-pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol. Neuropsychopharmacol., 3, 117-126.
7. BROWN, A.M., KUNZE, D.L. & YATANI, A. (1984). The agonist effect of dihydropyridines on Ca channels. Nature, 311, 570-572.
8. 1 ligand. J. Med. Chem., 37, 2285-2291.
9. CHOI, D.W. (1987). Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res., 403, 333-336.
10. CHOMCZNSKI, P. & SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
11. CHOU, Y.C., LIAO, J.F., CHANG, W.Y., LIN, M.F. & CHEN, C.F. (1999). Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res., 821, 516-519.
12. CRANSTON, J.W. & YOAST, R. (1999). Abuse of dextromethorphan. Arch. Fam. Med., 8, 99-100.
13. CURRAN, T., GORDON, M.B., RUBINO, K.L. & SAMBUCETTI, L.C. (1987). Isolation and characterization of c-fos cDNA and analysis of post-translational modification in vitro. Oncogene, 2, 79-84.
14. FERKANY, J.W., BOROSKY, S.A., CLISSOLD, D.B. & PONTECORVO, M.J. (1988). Dextromethorphan inhibits NMDA-induced convulsions. Eur. J. Pharmacol., 151, 151-154.
15. FORT, P., MARTY, L., PIECHACZYK, M., SABROUTY, E., DANI, C., JEANTEUR, P. & BLANCHARD, J.M. (1985). Various rat adult tissues express only one major mRNA species from glyceraldehydes-3-phosphate dehydrogenase mutagen family. Nucleic Acids Res., 13, 1431-1442.
16. GOTTI, B., BENAVIDES, J., MACKENZIE, E.T. & SCATTON, B. (1990). The pharmacotherapy of focal cortical ischaemia in the mouse. Brain Res., 522, 290-307.
17. 3H]ifenprodil binding to sigma receptors in rat brain. Eur. J. Pharmacol., 236, 159-163.
18. HASHIMOTO, K. & LONDON, E.D. (1995). Interaction of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of σ receptors. Eur. J. Pharmacol., 273, 307-310.
19. 3H]ifenprodil binding in rat brain. Eur. J. Pharmacol., 266, 67-77.
20. HOLTZMAN, S.G. (1994). Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology, 116, 249-254.
21. IDA, H. (1997). The nonnarcotic antitussive drug dimemorfan: a review. Clin. Ther., 19, 215-231.
22. JHOO, W.K., SHIN, E.J., LEE, Y.H., CHEON, M.A., OH, K.W., KANG, S.Y., LEE, C., YI, B.C. & KIM, H.C. (2000). Dual effects of dextromethorphan on cocaine-induced conditioned place preference in mice. Neurosci. Lett., 288, 76-80.
23. KASÉ, Y., KITO, G., MIYATA, T., UNO, T., TAKAHAMA, K. & IDA, H. (1976). Antitussive activity and other related pharmaceutical properties of D-3-methyl-N-methylmorphinan (AT-17). Arzneim-Forsch. (Drug Res.), 26, 353-360.
24. KIM, H.C., BING, G., JHOO, W.K., KIM, W.K., SHIN, E.J., IM, D.H., KANG, K.S. & KO, K.H. (2003a). Metabolism to dextrorphan is not essential for dextromethorphan's anticonvulsant activity against kainate in mice. Life Sci., 72, 769-783.
25. KIM, H.C., BING, G., JHOO, W.K., KO, K.H., KIM, W.K., LEE, D.C., SHIN, E.J. & HONG, J.S. (1999). Dextromethorphan modulates the AP-1 DNA binding activity induced by kainic acid. Brain Res., 824, 125-132.
26. KIM, H.C., JHOO, W.K., KIM, W.K., SHIN, E.J., CHEON, M.A., SHIN, C.Y. & KO, K.H. (2001c). Carbetapentane attenuates kainate-induced seizures via σ-1 receptor modulation. Life Sci., 69, 915-922.
27. KIM, H.C., KO, K.H., KIM, W.K., SHIN, E.J., KANG, K.S., SHIN, C.Y. & JHOO, W.K. (2001a). Effects of dextromethorphan on the seizures induced by kainate and the calcium channel angonist BAY k-8644: comparison with the effects of dextrorphan. Behav. Brain Res., 120, 169-175.
28. KIM, H.C., LEE, P.H. & JHOO, W.K. (1998). The complex pharmacological action of dextromethorphan; requirement of development of neuroprotective dextromethorphan analogs with negligible psychotomimetic effects. International Symposium on the Molecular Monitoring in the Neuroscience Field, Vol 3. Nagoya, Japan, pp. 1-2.
29. KIM, H.C., NABESHIMA, T., JHOO, W.K., KO, K.H., KIM, W.K., SHIN, E.J., CHO, M. & LEE, P.H. (2001b). Anticonvulsant effects of new morphinan derivatives. Bioorg. Med. Chem. Lett., 11, 1651-1654.
30. KIM, H.C., PENNYPACKER, K., BING, G., BRONSTEIN, D., MCMILLIAN, M. & HONG, J.S. (1996). The effect of dextromethorphan on kainic acid-induced seizures in the rat. Neurotoxicology, 17, 375-386.
31. KIM, H.C., SHIN, C.Y., SEO, D.O., JHOO, J.H., JHOO, W.K., KIM, W.K., SHIN, E.J., LEE, Y.H., LEE, P.H. & KO, K.H. (2003b). New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. Life Sci., 72, 1883-1895.
32. KOPCHIK, T.T., CULLEN, R. & STAGEY, D.W. (1981). Rapid analysis of small nucleic acid samples by gel electrophoresis. Anal. Biochem., 115, 419-423.
33. KURIHARA, J., TAMAOKI, S. & KATO, H. (1993). Blockade of alpha 2-adrenoreceptors protects the vagal baroreflex system from transient global cerebral ischemia in dogs. Eur. J. Pharmacol., 240, 73-76.
34. KWON, Y.S., ANN, H.S., NABESHIMA, T., SHIN, E.J., KIM, W.K., JHOO, J.H., JHOO, W.K., WIE, M.B., KIM, Y.S., JANG, K.J. & KIM, H.C. (2004). Selegiline potentiates the effects of EGb 761 in response to ischemic brain injury. Neurochem. Int., 45, 157-170.
35. LEANDER, J.D. (1989). Evaluation of dextromethorphan and carbetapentane as anticonvulsants and N-methyl-D-asparatic acid antagonists in mice. Epilepsy Res., 4, 28-33.
36. LIU, Y., QIN, L., LI, G., ZHANG, W., AN, L., LIU, B. & HONG, J.S. (2003). Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther., 305, 212-218.
37. LOSCHER, W & HONACK, D. (1993). Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Eur. J. Pharmacol., 238, 191-200.
38. MATSUMOTO, R.R., BOWEN, W.D., TOM, M.A., VO, V.N., TRUONG, D.D. & DE COSTA, B.R. (1995). Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism. Eur. J. Pharmacol., 280, 301-310.
39. MCCANN, D.J., WEISSMAN, A.D. & SU, T.P. (1994). Sigma-1 and sigma-2 sites in rat brain: comparison of regional, ontogenetic, and subcellular patterns. Synapse, 17, 182-189.
40. MCCRACKEN, K.A., BOWEN, W.K., DE COSTA, B.R. & MATSUMOTO, R.R. (1999). Two novel sigma receptor ligands, BD 1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol., 370, 225-232.
41. 3H]ifenprodil. Mol. Pharmacol., 54, 591-598.
42. MORGAN, J.L. & CURRAN, T. (1991). Proto-oncogene transcription factors and epilepsy. Trends Pharmacol. Sci., 12, 343-349.
43. MURAKAMI, M., INUKAI, N. & NAGANO, N. (1972). Studies on morphinan derivatives I. The synthesis of several new 3-substituted derivatives of N-methylmorphinan ring having antitussive activities. Chem. Pharm. Bull., 20, 1699-1705.
44. NETZER, R., PFLIMLIN, P. & TRUBE, G. (1993). Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur. J. Pharmacol., 238, 209-216.
45. NODA, Y., YAMADA, K., FURUKAWA, H. & NABESHIMA, T. (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmacol., 116, 2531-2537.
46. NOONAN, W.C., MILLER, W.R. & FEENEY, D.M. (2000). Dextromethorphan abuse among youth. Arch. Fam. Med., 9, 791-792.
47. PARK, S.Y., SHIN, E.J., JHOO, W.K., KO, K.H., KIM, W.K. & KIM, H.C. (2002). Dimemorfan provides neuroprotection via activation of sigma-1 receptor and blocking L-type calcium channels; models of kainate and BAY k-8644. Soc. Neurosci. (abstract), 32, program no 798.5.
48. PENNYPACKER, K., HONG, J.S. & MCMILLIAN, M. (1995). Implications of prolonged expression of Fos-related antigens. Trends Pharmacol. Sci., 16, 317-321.
49. PRICE, L.H. & LEBEL, J. (2000). Dextromethorphan-induced psychosis. Am. J. Psychiatry, 157, 304.
50. RACINE, R.J. (1972). Modification of seizure activity by eletrical stimulation: motor seizure. EEG Clin. Nuerophysiol., 32, 281-294.
51. RAMMER, L., HOLMGREN, P. & SANDLER, H. (1988). Fatal intoxication by dextromethorphan: a report on two cases. Forensic Sci. Int., 37, 766-768.
52. 3H]1,3-D1(2-tolyl)guanidine labels two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel blockers and sigma ligands. NIDA Res. Mongr., 105, 335-336.
53. SHIN, E.J., JHOO, J.H., KIM, W.K., JHOO, W.K., LEE, C., JUNG, B.D. & KIM, H.C. (2004a). Protection against kainate neurotoxicity by pyrrolidine dithiocarbamate. Clin. Exp. Pharmacol. Physiol., 31, 320-326.
54. SHIN, E.J., NABESHIMA, T., LEE, P.H., KIM, W.K., KO, K.H., JHOO, J.H., JHOO, W.K., CHA, J.Y. & KIM, H.C. (2004b). Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice. Behav. Brain Res., 151, 267-276.
55. SPERK, G. (1994). Kainic acid seizures in the rat. Prog. Neurobiol., 42, 1-32.
56. TORTELLA, F.C. & MUSACCHIO, J.M. (1986). Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties. Brain Res., 383, 314-318.
57. TORTELLA, F.C., PELLICANO, M. & BOWERY, N.G. (1989). Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol. Sci., 10, 501-507.
58. TORTELLA, F.C., ROBLES, L., WITKEN, J.M. & NEWMAN, A.H. (1994). Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. J. Pharmacol. Exp. Ther., 268, 727-733.
59. WALKER, J.M., BOWEN, W.D., WALKER, F.O., MATSUMOTO, R.R., DECOSTA, B. & RICE, K.C. (1990). Sigma receptors: biology and function. Pharmacol. Rev., 42, 355-402.
60. WANG, H.H., CHIEN, J.W., CHOU, Y.C., LIAO, J.F. & CHEN, C.F. (2003). Anti-amnesic effect of dimemorfan in mice. Br. J. Pharmacol., 138, 941-949.
61. WITKIN, J.M. & ACRI, J.B. (1995). Effects of ifenprodil on stimulatory, discriminative stimulus, and convulsant effects of cocaine. Behav. Pharmacol., 6, 245-253.
62. WON, J.S., KIM, Y.H., SOING, D.K. & SUH, H.W. (1997). The effects of cycloheximide on the regulation of proenkephalin and prodynorphan gene expressions induced by kainic acid in rat hippocampus. Mol. Bain Res., 47, 303-310.
63. YIN, K.J. & SUN, F.Y. (1999). Effect of dextromethorphan, a NMDA antagonist, on DNA repair in rat photochemical thrombotic cerebral ischemia. Brain Res., 815, 29-35.
64. ZHOU, G.Z. & MUSACCHIO, J.M. (1991). Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain. Eur. J. Pharmacol., 206, 261-269.